nasal delivery

Neffy FDA rejection, ARS Pharmaceuticals nasal spray epinephrine, Neffy vs EpiPen, Neffy appeal and resubmission, Neffy anaphylaxis treatment, ARS Pharmaceuticals stock price SPRY, Neffy repeat-dose study,

FDA denies approval for Neffy, ARS Pharmaceuticals’ needle-free EpiPen alternative, citing safety concerns

Anika Sharma

While positive votes from FDA advisory committees often bode well for drug approvals, ARS Pharmaceuticals experienced an unexpected setback when ...